156 related articles for article (PubMed ID: 33171128)
1. Can Genomic Sequencing Identify High-Risk Barrett's Esophagus Earlier Than Pathologists?
Stachler MD; Bass AJ
Cancer Cell; 2020 Nov; 38(5):626-628. PubMed ID: 33171128
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Esophageal Adenocarcinoma Risk Using Somatic Chromosome Alterations in Longitudinal Samples in Barrett's Esophagus.
Li X; Paulson TG; Galipeau PC; Sanchez CA; Liu K; Kuhner MK; Maley CC; Self SG; Vaughan TL; Reid BJ; Blount PL
Cancer Prev Res (Phila); 2015 Sep; 8(9):845-56. PubMed ID: 26130253
[TBL] [Abstract][Full Text] [Related]
3. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus.
Zou H; Molina JR; Harrington JJ; Osborn NK; Klatt KK; Romero Y; Burgart LJ; Ahlquist DA
Int J Cancer; 2005 Sep; 116(4):584-91. PubMed ID: 15825175
[TBL] [Abstract][Full Text] [Related]
4. Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus.
Whitson MJ; Falk GW
Gastroenterol Clin North Am; 2015 Jun; 44(2):299-315. PubMed ID: 26021196
[TBL] [Abstract][Full Text] [Related]
5. Genetic and Epigenetic Alterations in Barrett's Esophagus and Esophageal Adenocarcinoma.
Kaz AM; Grady WM; Stachler MD; Bass AJ
Gastroenterol Clin North Am; 2015 Jun; 44(2):473-89. PubMed ID: 26021206
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers of Barrett's Esophagus: From the Laboratory to Clinical Practice.
Konda VJA; Souza RF
Dig Dis Sci; 2018 Aug; 63(8):2070-2080. PubMed ID: 29713984
[TBL] [Abstract][Full Text] [Related]
7. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus.
Levine DS; Haggitt RC; Blount PL; Rabinovitch PS; Rusch VW; Reid BJ
Gastroenterology; 1993 Jul; 105(1):40-50. PubMed ID: 8514061
[TBL] [Abstract][Full Text] [Related]
8. Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma.
Reid BJ; Haggitt RC; Rubin CE; Rabinovitch PS
Gastroenterology; 1987 Jul; 93(1):1-11. PubMed ID: 3582897
[TBL] [Abstract][Full Text] [Related]
9. Screening and Surveillance for Barrett's Esophagus: Is It Cost-Effective?
Inadomi JM; Saxena N
Dig Dis Sci; 2018 Aug; 63(8):2094-2104. PubMed ID: 29948571
[TBL] [Abstract][Full Text] [Related]
10. The diagnosis and management of Barrett's esophagus.
DeMeester SR; DeMeester TR
Adv Surg; 1999; 33():29-68. PubMed ID: 10572561
[TBL] [Abstract][Full Text] [Related]
11. Dedifferentiation precedes invasion in the progression from Barrett's metaplasia to esophageal adenocarcinoma.
Helm J; Enkemann SA; Coppola D; Barthel JS; Kelley ST; Yeatman TJ
Clin Cancer Res; 2005 Apr; 11(7):2478-85. PubMed ID: 15814623
[TBL] [Abstract][Full Text] [Related]
12. TP53 mutations in malignant and premalignant Barrett's esophagus.
Dolan K; Walker SJ; Gosney J; Field JK; Sutton R
Dis Esophagus; 2003; 16(2):83-9. PubMed ID: 12823203
[TBL] [Abstract][Full Text] [Related]
13. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
[TBL] [Abstract][Full Text] [Related]
14. DNA methylation as an adjunct to histopathology to detect prevalent, inconspicuous dysplasia and early-stage neoplasia in Barrett's esophagus.
Alvi MA; Liu X; O'Donovan M; Newton R; Wernisch L; Shannon NB; Shariff K; di Pietro M; Bergman JJ; Ragunath K; Fitzgerald RC
Clin Cancer Res; 2013 Feb; 19(4):878-88. PubMed ID: 23243219
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: predictors of progression and prognosis.
Ong CA; Lao-Sirieix P; Fitzgerald RC
World J Gastroenterol; 2010 Dec; 16(45):5669-81. PubMed ID: 21128316
[TBL] [Abstract][Full Text] [Related]
16. Predictors of dysplastic and neoplastic progression of Barrett’s esophagus.
Alnasser S; Agnihotram R; Martel M; Mayrand S; Franco E; Ferri L
Can J Surg; 2019 Apr; 62(2):93-99. PubMed ID: 30907564
[TBL] [Abstract][Full Text] [Related]
17. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation.
Kimchi ET; Posner MC; Park JO; Darga TE; Kocherginsky M; Karrison T; Hart J; Smith KD; Mezhir JJ; Weichselbaum RR; Khodarev NN
Cancer Res; 2005 Apr; 65(8):3146-54. PubMed ID: 15833844
[TBL] [Abstract][Full Text] [Related]
18. Advanced Endoluminal Technologies for Barrett's Esophagus: Focus on Optical Coherence Tomography and Confocal Laser Endomicroscopy.
Zihni AM; DeMeester SR
Thorac Surg Clin; 2018 Nov; 28(4):465-472. PubMed ID: 30268292
[TBL] [Abstract][Full Text] [Related]
19. Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinoma.
Zou H; Osborn NK; Harrington JJ; Klatt KK; Molina JR; Burgart LJ; Ahlquist DA
Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):830-4. PubMed ID: 15824152
[TBL] [Abstract][Full Text] [Related]
20. Beyond Dysplasia Grade: The Role of Biomarkers in Stratifying Risk.
Dunbar KB; Souza RF
Gastrointest Endosc Clin N Am; 2017 Jul; 27(3):447-459. PubMed ID: 28577766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
